Clinical Report: Differentiating Castleman Disease from Systemic Lupus Erythematosus

Overview

Castleman disease (CD) can closely mimic systemic lupus erythematosus (SLE), leading to diagnostic challenges and potential misclassification. Key distinguishing features include the underlying cytokine dysregulation in CD, which necessitates different therapeutic approaches compared to SLE.

Background

Castleman disease is a rare lymphoproliferative disorder that presents with a range of systemic inflammatory symptoms, often overlapping with those of systemic lupus erythematosus. This diagnostic overlap can lead to inappropriate treatment strategies if not recognized, emphasizing the need for heightened awareness among clinicians. Accurate differentiation is crucial, as the management of CD requires cytokine-directed therapies rather than conventional immunosuppressive treatments used for SLE.

Data Highlights

No numerical data or trial data presented in the article.

Key Findings

• iMCD can present with symptoms that fulfill SLE classification criteria but may not respond to standard immunosuppressive therapy.
• Histopathological examination of lymph nodes is essential for accurate diagnosis of CD.
• Both conditions can present with fever, lymphadenopathy, cytopenias, and elevated inflammatory markers.
• Autoantibodies may be present in some iMCD patients, complicating the diagnosis.
• Therapeutic strategies differ significantly, with iMCD requiring IL-6 blockade rather than broad immunosuppression.

Clinical Implications

Clinicians should maintain a high index of suspicion for Castleman disease in patients presenting with lupus-like symptoms, especially when there is a lack of response to typical lupus treatments. Early recognition and appropriate diagnostic testing can prevent misclassification and ensure timely, effective management.

Conclusion

Increased awareness of the diagnostic overlap between Castleman disease and systemic lupus erythematosus is essential for improving patient outcomes. Accurate diagnosis allows for the implementation of appropriate treatment strategies tailored to the underlying pathology.

References

1. Associated Press Health, AP News, 2023 -- Woman's lupus journey sheds light on how the body attacks itself in autoimmune diseases
2. The ASCO Post, ASCO Post, 2025 -- Using AI to Identify Treatment Options for Castleman Disease
3. International Society of Hematology, Blood, 2017 -- International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease
4. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial - PubMed
5. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update, EULAR, 2023
6. Retinal Physician — Lab Testing in Posterior Noninfectious Uveitis: What, When and Why?
7. Clinical Rheumatology — Clinical and Serological Links of Urinary Activated Leukocyte Cell Adhesion Molecule in Systemic Lupus Erythematosus and Associated Lupus Nephritis
8. International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease | Blood | American Society of Hematology
9. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial - PubMed
10. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update